Introduction

prostatectomy.
The collection and analysis of all data were approved by the Institutional Review Boards of Inje University Paik Hospital, Pusan National University Hospital, and the Cancer Institute of New Jersey. Both Caucasian and African-Americans were included.
We respectively reviewed radical prostatectomy data and compared characteristics including age, preoperative prostate-specific antigen (PSA) levels, prostate-specific antigen density (PSAD), body mass index (BMI), Gleason score, and pathological T stage. BMI was classified by the Steering Committee of the Regional Office for the Western Pacific Region of WHO (WPRO) criteria (Anuurad et al., 2003) .
Statistical analysis
The SPSS software (ver. 18) was used for all analyses. Demographic, clinical, and pathological characteristics were examined. Data were presented as means and standard deviation. Clinical variables, such as age, PSA, BMI, and prostate size, in both groups were compared using Student's t-test and categorical variables were compared using chi-squared tests and Fisher's exact test.
Univariate and multivariate linear regression analyses were used to examine the predictive value of the clinicopathological features for preoperative PSA level. p values of <0.05 were considered to indicate statistical significance.
Results
The clinical and pathological characteristics of the prostate cancer patients in the two countries are summarized in Table 1 . Of the 1,159 cases, 507 (43.7%) were Koreans and 657 (56.3%) were Americans.
At diagnosis, there was a significant difference in mean age (67.1±6.6 years in Koreans vs 59.2±6.7 years in Americans; p=0.0001). The mean preoperative PSA level was higher in Koreans (15.4±17.9 ng/mL for Koreans vs. 6.2±4.6 ng/mL for Americans). The prostate of Koreans was smaller than that of Americans (p=0.0001; Table  1 ). Although there was no difference in pathological T stage, the overall pathological Gleason score was higher in Koreans (p=0.0001). Next, we analyzed the characteristics of the prostate cancer according to age, preoperative PSA levels, and BMI in both groups. According to age, Korean in their 50s had more advanced-stage cancers than Americans (p=0.021). In particular, Korean had more aggressive Gleason scores in those under 70 years old, while Americans had higher Gleason score in those over 71 years old (Table 2) . While prostate cancer in Koreans occurring in males older than 60 accounted for 84.5% (424/507), 84.9% (558/657) of the Americans were between 50 and 70 years old (Table  2) .
According to preoperative PSA levels, there was no difference in terms of Gleason score between the two groups below 10 ng/mL (p>0.05). Koreans had higher Gleason scores than Americans with a PSA above 10 ng/ mL (p<0.05; Table 3 ). According to preoperative PSA levels, there was no difference in pathological T stage between the groups.
According to BMI, there was no difference in terms of Gleason score or pathological stage between the groups (Table 4) . We also analyzed PSA according to Gleason score and prostate size between the groups. PSA levels in Korean were elevated with increasing prostate size and Gleason score compared with those of Americans (Table 5) .
We then compared Gleason score and preoperative PSA level according to pathological T stage in the two groups (Table 6 ). In pT2, Koreans had unfavorable Gleason scores; at identical Gleason scores, Koreans had higher PSA levels than Americans (p <0.001). In patients with pT3 and above, there was a significant difference between Koreans and Americans in terms of Gleason scores and PSA levels (Table 6) .
On univariate analysis, the following five variables were significant factors for high PSA levels: residence (American vs Korean), age, BMI, Gleason score, and pathological T stage. However, on multivariate linear regression analysis, place of residence (American vs Korean), Gleason sore, and pathological T stage remained strong and independent factors for elevated PSA; place of residence was a strong factor (Table 7) .
Discussion
The present study showed that Koreans with localized or locally advanced prostate cancer had poorer characteristics than similar Americans. In particular, Korean prostate cancer patients between 50 and 60 years old had higher Gleason scores and higher T stages than Americans.
The PSA test for the diagnosis of prostate cancer has been used in Korean for 20 years. Although its value as a screening test is controversial (Ilic et al., 2013) , the PSA test is widely used in many countries, including Korea and the US. Since the PSA testing era began, the incidence of prostate cancer in Asian populations, including Korea, has been found to be lower than that in Western countries (Center et al., 2012) . However, the average annual percentage change (AAPC) in Asia over the last 10 years has been high; indeed, the AAPC in Korea was 13.8 between 1999 and 2007, which is the most rapid increase globally (Center et al., 2012) .
Today, the risk factors for prostate cancer are believed to include advanced age, genetic variation, race, geographic variation, and diet (Center et al., 2012; Pan et al., 2012; Tabung et al., 2012; Wood et al., 2012) . Several studies have shown differences in prostate cancer according to race in terms of incidence, pathological differentiation, and outcomes. A study of the geographic variation in prostate cancer incidence in 40 countries showed that North America, and western and northern Europe had the highest prostate cancer incidence and that the incidence in Asia was among the lowest between 2000 and 2006 (Center et al., 2012 ). An investigation in the US analyzed the prostate cancer characteristics of 8,840 Asians in California between 1995 and 2004 (Robbins et al., 2007) . Though the Korean population comprised only a small proportion of this (0.03%), the incidence of prostate cancer in the US increased gradually over a 10-year period. For a similar period (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) , the age-standardized cancer incidence of prostate cancer in Korea increased markedly from 8.4 to 24.8 per 100,000 (Jung et al. 2012a ). Indeed, the annual percentage increase is second only to that of thyroid cancer.
Several studies have reported that Asians resident in North America have more aggressive cancers compared with Caucasians or African-Americans (Lin et al., 2002; Robbins et al., 2007) . Robbins et al. reported that the proportion of white residents with poorly differentiated histological grade (Gleason score 8 10) was 22.9%, while those of Koreans, Chinese, and Japanese males in California were 34.5%, 30.9%, and 28.6%, respectively (Robbins et al., 2007) . Furthermore, the proportion of poorly differentiated cancers, Gleason scores, and advanced stage in Koreans was the highest among the Asians examined. In this study, the proportion with a Gleason score ≥7 was higher in Koreans (66.9%) than Americans (55.7%). Most notably, Koreans younger than 70 years and with PSA >10 ng/mL showed considerably higher risk of more unfavorable Gleason scores than Americans in this study (Tables 3, 5) . Also, in the same Gleason score group, preoperative PSA levels in Koreans were higher than in Americans, by 1.7-2.5 fold (mean PSA levels; see Table 6 ). Kim et al. reported changes in Gleason Score in prostate cancer over the last 12 years in a Korean population (Kim et al., 2012) . In total, 2,508 prostate cancer patients undergoing radical prostatectomies were enrolled. Over the 12 years, most of the prostate cancer was poorly differentiated, with Gleason scores of 7-10 (81.8%), although the proportion with a Gleason score of 6 increased slightly, from 15.0-18.2%. Also, the Surveillance, Epidemiology, and End Results (SEER) study data showed that Asian residents in the US had more distant metastases than Caucasians at the time of diagnosis during the period 1988-1994 (Lin et al., 2002) .
In contrast to these unfavorable findings, some researchers have reported good results in Asians. Although a small number of Asians (5%) were included, in residents of the eastern US, there was no difference by race in Gleason score, compared with Caucasian and AfricanAmericans (Raymundo et al., 2011) . Some investigators have suggested that Asian populations have a good prognosis, rather than poor characteristics (Robbins et al. 2007 ). In fact, Asians in the US had better survival than other races, including Caucasians, African-Americans, and Hispanics, according to the SEER data (Siegel R et al., 2012) . Although the mortality rate for Caucasians was 22.4 per 100,000 population, that for Asians was 10.5 per 100,000 population.
As shown in Table 2 , in Americans, older patients tended to present with higher Gleason scores. However, prostate cancer in older Koreans showed consistently lower Gleason scores.
Prostate cancer in Koreans aged 50 years or younger represented a small proportion (0.8%). The proportion in those between 50 and 60 years old was up to 14.7%. Although these data may not be representative of all Korean males, urologists should consider the possibility of prostate cancer in such individuals.
Our study had several limitations. First, we did not review pathological findings centrally. Second, there may have been selection bias, because of the regional nature of the data (Busan in Korea and New Jersey in US) in the two countries. Third, in this study, no prognosis or outcome information after the radical prostatectomies was available for comparison, only tumor nature, because the outcome and prognosis of prostate cancer would be affected by the surgeons' technical skill and operative methods (open, laparoscopic, robotics) . Despite these limitations, this is the first head-to-head comparison of prostate cancer in Koreans and Americans during the same period.
In conclusions, this present study shows that the characteristics of prostate cancer in Koreans differ from those in Americans. In particular, Koreans in their 50s and 60s have worse pathological findings than Americans and more advanced pathological T stages in their 50s. Thus, this study suggests that new treatment strategies, focused on Koreans, may be needed for the management of prostate cancer.
